Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia

NCT05399888 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT05399888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05399888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 24, 2022
Completion date
June 6, 2028
Enrollment
416 (actual)
Sites
138

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease dementia, mild cognitive impairment due to alzheimer's disease